IL-17A in COVID-19 Cases: A meta-analysis

Loading...
Thumbnail Image

Date

Journal Title

Journal ISSN

Volume Title

Publisher

Journal of Infection in Developing Countries

Abstract

Introduction: Numerous reviews, commentaries and opinion pieces have suggested targeting IL-17A as part of managing Coronavirus disease 2019 (COVID-19), the notorious pandemic caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). IL-17A is a proinflammatory cytokine attributed with homeostatic roles but that is also involved in autoimmune disease pathogenesis. While some studies have reported an increase in IL-17A in COVID-19 cases, no significant associations were found by others. Hence, we undertook this meta-analysis to study serum IL-17A levels in COVID-19 patients in relation to disease severity. Methodology: Multiple databases were systematically reviewed for literature published on the topic from January 1, 2019 to April 30, 2021. A random effects model was used to calculate weighted mean differences (WMDs) and 95% confidence interval (CIs) as well as the τ2 and I2 statistics for heterogeneity analysis. Results: We report that IL-17A increases in COVID-19 subjects irrespective of disease severity compared to controls [WMD = 2.51 pg/ml (95% CI 1.73-3.28), p < 0.00001]. It is also higher in patients with moderate disease compared to controls [WMD = 2.41 pg/ml (95% CI:1.40-3.43), p < 0.00001] as well as higher in patients with severe COVID-19 [WMD = 4.13 pg/ml (95% CI:1.65-6.60), p = 0.001]. While the increase in serum levels in subjects with severe disease over those with moderate disease was statistically significant, the association was not as robust as the other comparisons [WMD = 2.07 pg/ml (95% CI:0.20-3.95), p = 0.03]. Variable heterogeneity was observed in the various analyses with no significant publication bias detected. Conclusions: Hence, IL-17A may be of relevance when considering management approaches to COVID-19. Copyright © 2021 Fadlallah et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Description

Keywords

Covid-19, Il-17a, Sars-cov-2, Global health, Humans, Interleukin-17, Pandemics, Interleukin 17, Il17a protein, human, Article, Blood sampling, Clinical outcome, Coronavirus disease 2019, Disease severity, Hospital admission, Human, Immune response, Meta analysis, Severe acute respiratory syndrome coronavirus 2, Systematic review, Th17 cell, Blood, Pandemic

Citation

Endorsement

Review

Supplemented By

Referenced By